WallStreetZenWallStreetZen

NASDAQ: NSPR
Inspiremd Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for NSPR

Based on 1 analyst offering 12 month price targets for Inspiremd Inc.
Min Forecast
$4.50+87.5%
Avg Forecast
$4.50+87.5%
Max Forecast
$4.50+87.5%

Should I buy or sell NSPR stock?

Based on 1 analyst offering ratings for Inspiremd Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their NSPR stock forecasts and price targets.

NSPR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-11-02Find Out Why

1 of 1

Forecast return on equity

Is NSPR forecast to generate an efficient return?

Forecast return on assets

Is NSPR forecast to generate an efficient return on assets?

NSPR revenue forecast

What is NSPR's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$6.1M+11.52%
Avg 2 year Forecast
$7.2M+30.71%
Avg 3 year Forecast
$14.3M+162.16%
NSPR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NSPR revenue growth forecast

How is NSPR forecast to perform vs Medical Devices companies and vs the US market?
Company
34.52%
Industry
6.18%
Market
7.56%
NSPR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NSPR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NSPR vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
NSPR$2.40$4.50+87.50%Strong Buy
CTSO$1.19$4.75+299.16%Strong Buy
RBOT$0.30$9.00+2,870.30%Strong Buy
EAR$2.60N/AN/A
NVNO$3.71N/AN/A
View Top Medical Device Stocks

Inspiremd Stock Forecast FAQ

Is Inspiremd Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: NSPR) stock is to Strong Buy NSPR stock.

Out of 1 analyst, 1 (100%) are recommending NSPR as a Strong Buy, 0 (0%) are recommending NSPR as a Buy, 0 (0%) are recommending NSPR as a Hold, 0 (0%) are recommending NSPR as a Sell, and 0 (0%) are recommending NSPR as a Strong Sell.

If you're new to stock investing, here's how to buy Inspiremd stock.

What is NSPR's revenue growth forecast for 2023-2025?

(NASDAQ: NSPR) Inspiremd's forecast annual revenue growth rate of 34.52% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 6.18%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.56%.

Inspiremd's revenue in 2023 is $5,470,000.On average, 1 Wall Street analysts forecast NSPR's revenue for 2023 to be $131,452,798, with the lowest NSPR revenue forecast at $131,452,798, and the highest NSPR revenue forecast at $131,452,798. On average, 1 Wall Street analysts forecast NSPR's revenue for 2024 to be $154,079,919, with the lowest NSPR revenue forecast at $154,079,919, and the highest NSPR revenue forecast at $154,079,919.

In 2025, NSPR is forecast to generate $309,021,823 in revenue, with the lowest revenue forecast at $309,021,823 and the highest revenue forecast at $309,021,823.

What is NSPR's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: NSPR) forecast ROA is N/A, which is lower than the forecast US Medical Devices industry average of -0.01%.

What is NSPR's Price Target?

According to 1 Wall Street analyst that have issued a 1 year NSPR price target, the average NSPR price target is $4.50, with the highest NSPR stock price forecast at $4.50 and the lowest NSPR stock price forecast at $4.50.

The Wall Street analyst predicted that Inspiremd's share price could reach $4.50 by Nov 2, 2024. The average Inspiremd stock price prediction forecasts a potential upside of 87.5% from the current NSPR share price of $2.40.

What is NSPR's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: NSPR) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.